Ann: PharmAust Presentation, page-53

Not really diffiucult. When monepantel's anti-cancer properties were first studied by professor Morris et al of UNSW back in 2013-14, it became apparent that it was acting as an mTOR inhibitor that was upregulating the autophagy process. As studies proceeded in the neurodegenerative science, it was becoming increasingly clear that one of the problems was a lack of autophagy. So Mollard and Aston of PharmAust put two and two together in regard to the possibility that monepantel could be useful for treating neurodegenerative diseases as well.